Upload File

egress of cd19 + cd5 + cells into peripheral blood following treatment with the bruton tyrosine...

  • Home
  • Documents
  • Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
8
Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients by Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, and Laurence Elias Blood Volume 122(14):2412-2424 October 3, 2013 ©2013 by American Society of Hematology

Upload: talon-shugar

Post on 01-Apr-2015

225 views

Category:

Documents


2 download

Report

Tags:

TRANSCRIPT

Page 1: Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor

ibrutinib in mantle cell lymphoma patients

by Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman,

Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, and Laurence Elias

BloodVolume 122(14):2412-2424

October 3, 2013

©2013 by American Society of Hematology

Page 2: Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Transient mobilization of lymphocytes in MCL patients treated with ibrutinib.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Page 3: Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

CD19+CD5+ cells have decreased CXCR4, CD38, and Ki67 expression following ibrutinib treatment.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Page 4: Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Ibrutinib inhibits migration of MCL cells beneath stromal cells (pseudo-emperipoiesis) and the formation of CXCL12-stimulated cortical actin.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Page 5: Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Ibrutinib suppresses BCR- and coculture-stimulated signaling and cytokine and chemokine production of MCL cells.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Page 6: Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Ibrutinib inhibits BCR-activated adhesion of MCL cells.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Page 7: Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Ibrutinib inhibits CXCL12-/CXCL13-activated adhesion and migration of MCL cells.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Page 8: Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Ibrutinib inhibits BCR- and chemokine-induced adhesion of primary MCL cells.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology


Ibrutinib treatment ameliorates murine chronic graft

Ibrutinib inhibition of Bruton protein-tyrosine kinase ... · Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) ... Covalent protein kinase inhibitors ... The role of Bruton

CONTRAINDICATIONS--------------------------- · 7 DRUG INTERACTIONS . 7.1 Effect of CYP3A Inhibitors on Ibrutinib . 7.2 Effect of CYP3A Inducers on Ibrutinib . USE IN SPECIFIC POPULATIONS

Ligation of immunoglobulin to CD19, CD21, B-cell

Ibrutinib capsules 140 mg price | natco ibrutinib Buy Online | Ibrunat 140mg Capsules Supplier

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 ... · Cancer Therapy: Preclinical The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells

Poster 7510 Long-term Efficacy and Safety With Ibrutinib

Product Code: NCL-L-CD19-163

CD5. TIch phan va ung dun.pdf

BD OneFlow LST8 Anti-TCRγ/δ-1, CD5, CD4, and CD8 can separate T cells into a number of subpopulations. CD19 and CD20 identify B cells, and together with CD45 can separate B cells

Abbreviated Title: Anti-CD19-CAR T cells

ASPHO 2019 Conference Paper and Poster Indexaspho.org/uploads/meetings/2019annualmeeting/2019_ASPHO_PBMTC... · patients, whether relapse was CD19+ or CD19-. MRD burden in BM was

Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at

Ibrutinib: Analysis of Pivotal Data

Ibrutinib‐associated bleeding: pathogenesis, management ... · Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 2017; 15:

Ibrutinib Treatment for First-Line and Relapsed/Refractory ......Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal

Ibrutinib-Associated Atrial Fibrillationelectrophysiology.onlinejacc.org/content/jcep/...STATE-OF-THE-ART REVIEW Ibrutinib-Associated Atrial Fibrillation Sarju Ganatra, MD,a, bAjay

Application to add ibrutinib to WHO Model List of

1083 Original Article CD5 and CD6 as immunoregulatory

IMBRUVICA- ibrutinib tablet, film coated

Treatment with Ibrutinib Inhibits BTK- and Dependent ... · Cancer Therapy: Preclinical Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic

The Synergy of Adenosine and Ibrutinib on Platelet

CD5-MEDIATED INHIBITION OF T LYMPHOCYTE SIGNALING · CD5-MEDIATED INHIBITION OF T LYMPHOCYTE SIGNALING ... A central role for Fyn in the CD5-mediated inhibition of T lymphocyte signaling

Quartz‐crystal Microbalance Measurements of CD19 Antibody

Ibrutinib Presentation

Sleeping Beauty (SB) modified CD19-specific T cells

The CD5 Series Laser Displacement Sensors from … CD5 Series Laser Displacement Sensors from Optex-FA ... 25 +/- 1 mm Resolution: 0.02 um ... The Specular type CD5-L25/CD5-LW25 can

Ublituximab and ibrutinib for previously treated genetically …...Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: results of the

Ublituximab and ibrutinib for previously treated ... 2017 Sharman Final.pdf · Ublituximab and ibrutinib for previously treated genetically ... Hansen, Adam Olszewski, ... and ibrutinib

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase ... · RESEARCH ARTICLE Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma Christian Grommes

Ibrutinib for treating chronic lymphocytic leukaemia [ID749]

Anonymous - Azazel Readings Cd19 Id247376279 Size2448

5.07IBRUTINIB,pbs.gov.au/.../2015-07/files/ibrutinib-psd-july-2015.docx · Web viewThis amendment allowed ofatumumab patients to crossover to ibrutinib upon disease progression, as

Sensor Head Instruction Manual Displacement … Head Instruction Manual ... ・CD5-L25 / CD5-LW25 ... Center 25mm 30mm 85mm 150mm 350mm 500mm 2,000mm

CD5: Child, Family and Community